STATEMENT OF NEED/TARGET AUDIENCE

Prostate cancer is one of the most rapidly evolving fields in urologic oncology. Published results from clinical trials lead to the emergence of new surgical and radiation therapy techniques and therapeutic agents, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist and radiation oncologist must be well informed of these advances. To bridge the gap between research and practice, Prostate Cancer Update utilizes a moderated forum with leading urologic oncology and radiation oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists urologists and radiation oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

• Critically evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, prevention and treatment and incorporate these data into management strategies in the local and advanced disease settings.
• Counsel appropriately selected patients about the availability of ongoing clinical trials.
• Inform prostate cancer patients about the specific risks and benefits of local and systemic therapies.
• Provide individualized counseling to patients regarding the choice and timing of endocrine therapy.
• Counsel appropriately selected patients in the high-risk or advanced disease settings about the risks and benefits of chemotherapy, including emerging data on taxane-based regimens.

PURPOSE OF THIS ISSUE OF PROSTATE CANCER UPDATE

The purpose of this special edition of Prostate Cancer Update is to support these global objectives by offering the perspectives of Drs Chodak, Crawford, Eisenberger, Freedland, Gomella, Keane, Klotz, Petrylak, Schellhammer, Scher, Zelefsky and Zippe on the integration of emerging clinical research data into the management of prostate cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs or tapes, review the monograph and complete the Post-test and Evaluation Form located in the back of this monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. ProstateCancerUpdate.com/ThinkTank includes an easy-to-use interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

Home